Altasciences Completes Expansion of New State-Of-The-Art Laboratory in Columbia, Missouri
31 Oct 2023
LAVAL, Québec--(BUSINESS WIRE)-- Altasciences is pleased to announce the completion of its laboratory facilities in Columbia, MO.
This press release features multimedia. View the full release here:
From left to right: Altasciences' Dr. Lynne Le Sauteur, Dr. Susan Ohorodnik, Ian Vanterpool, and Michael Qualls at the bioanalytical laboratory opening in Columbia, Missouri (Photo: Business Wire)
The newly expanded, 8,000-square-foot space, which includes a test material department, features state-of-the-art equipment and forty-eight workbenches, with a vast range of services, including ligand binding assays, flow cytometry, biomarker analysis, and cell culture capabilities.
“This laboratory expansion is a significant step forward in our ability to meet the increasing needs of sponsors. Our focus on growing our bioanalytical capabilities highlights Altasciences' mission to help develop potentially life-saving therapeutics, and get them to market faster,” said Marie-Hélène Raigneau, Co-chief Operating Officer, Altasciences. “Our integrated CRO/CDMO services combine bioanalytical services with preclinical and clinical study solutions, manufacturing services, and all complementary research support services, for maximum efficiency.”
This is Altasciences’ third purpose-built laboratory. Altasciences’ laboratory sciences has the scientific, regulatory, and operational expertise for quantitation of drugs and biomarkers from discovery to preclinical to Phase IV, using bioanalysis platforms including mass spectrometry, ligand binding assay, PCR, flow cytometry, ELISpot, and cell based assays in routine and specialized areas such as immunomodulation and cell and gene therapy. All three laboratories across North America are uniformly designed and managed.
Whether as a standalone bioanalytical service or as part of an integrated program, Altasciences provides top-quality data for TK, PK, and PD determinations to support preclinical and clinical studies.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. To learn more about Altasciences, visit altasciences.com.
View source version on businesswire.com:
Contacts
Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com
Source: Altasciences
Smart Multimedia Gallery
Photo
From left to right: Altasciences' Dr. Lynne Le Sauteur, Dr. Susan Ohorodnik, Ian Vanterpool, and Michael Qualls at the bioanalytical laboratory opening in Columbia, Missouri (Photo: Business Wire)
Logo
View this news release and multimedia online at:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.